Zhongfu Technology: Plans to acquire the controlling stake of CRO company Junke Zhengyuan, with an overall valuation of 1 billion yuan

Mars Finance News, April 26 — Zhongfu Technology announced that its wholly owned subsidiary, Dingfu Medical, plans to sign a “Framework Agreement on Equity Transfer” with Shanghai Jinpan, Shiguang Hengsheng, and others, to acquire control rights of the state-level specialized, innovative “Little Giant” enterprise Junke Zhengyuan and its integrated CRO assets. The target equity’s overall estimated value is 1 billion yuan. After the transaction is completed, the target company will be included in the scope of the company’s consolidated financial statements. Under the agreement, Dingfu Medical is required to pay an acquisition intent payment of no more than 30 million yuan. Regarding performance commitments, from 2026 to 2028, Junke Zhengyuan’s expected net profit after deducting non-recurring gains and losses will be no less than 66 million yuan, 77 million yuan, and 88 million yuan, respectively. This transaction does not constitute a related-party transaction or a major asset restructuring. The final proposal is subject to audit review and approval, and there is uncertainty. (Company Announcement)